Viewing Study NCT00510068

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:43 PM
Ignite Modification Date: 2026-02-04 @ 2:54 AM
Study NCT ID: NCT00510068
Status: COMPLETED
Last Update Posted: 2015-07-01
First Post: 2007-07-31
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced Neuroendocrine Tumors of Pancreatic Origin View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Phase III View
None Advanced Neuroendocrine Tumor in adults View
None RAD001 View
None NET View
None everolimus View
None mTOr View
None islet cell View
None neuroendocrine View